CanadaShedding light on selection patents: new business challenges

This is an Insight article, written by a selected partner as part of IAM's co-published content. Read more on Insight

The landscape of pharmaceutical patents has recently changed in Canada. A Supreme Court battle pitched generic drug company Apotex against Sanofi-Aventis over the validity of Sanofi-Aventis’s selection patent, which covers the anti-coagulating drug Plavix. The decision, in favour of Sanofi-Aventis, affirmed the patentability of Plavix even when one of Sanofi- Aventis’s earlier patents claimed a mixture that contained the drug, but which the Sanofi-Aventis scientists had not identified as being valuable.


Unlock unlimited access to all IAM content